drugset / Trial / NCT05982080
A Study to Investigate FP002 in Subjects With Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The goal of this phase 1 study is to assess the safety, and tolerability of FP002 to determine the dose recommended for dose expansion in subjects with advanced solid tumor.
Timeline
- Start
- 2023-08-02
- Primary completion
- 2025-04
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FP002 | Unknown | 0.3 mg/kg | Intravenous |
| Subject | FP002 | Unknown | 1 mg/kg | Intravenous |
| Subject | FP002 | Unknown | 3 mg/kg | Intravenous |
| Subject | FP002 | Unknown | 10 mg/kg | Intravenous |
| Subject | FP002 | Unknown | 20 mg/kg | Intravenous |
| Subject | FP002 | Unknown | 30 mg/kg | Intravenous |